SPOTLIGHT: Synta, GSK gain orphan drug designation


The FDA has granted its orphan drug designation to elesclomol, an investigational drug that treats metastatic melanoma. The drug is being advanced by a collaboration between Synta and GlaxoSmithKline. Release